Olaratumab, the first new monoclonal antibody drug for advanced soft tissue sarcoma
LI Fen-fen
ZHANG Dong-dong
LI Xiao-tian
Abstract：Olaratumab is an antibody against platelet-derived growth factor alpha receptor (PDGFR-α),the first monoclonal antibody against soft tissue sarcoma (STS).The FDA and EMA approved olaratumab to be used in combination with doxorubicin for STS patients with advanced histological subtypes,who are not suitable for radiotherapy and surgical treatment,but suitable for anthracycline treatment.In this paper,the status for treatment of STS,and the mechanism of action,pharmacokinetics,clinical research and safety of olaratumab were summarized.
Keywords：olaratumabplatelet-derived growth factor alpha receptor (PDGFR-α)soft tissue sarcomamonoclonal antibodyaccelerated review
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 2241-2244 )